Related Experiment Video
Updated: Jan 7, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
The value of PSMA PET for risk stratification in prostate cancer: an update and future aspects
Caner Civan1, Madeleine J Karpinski2, Kambiz Rahbar3
1Department of Nuclear Medicine, University Hospital Essen, German Cancer Consortium (DKTK), West German Cancer Center, Essen, Germany.
Abstract:
PSMA-PET has become a pivotal imaging method for staging and restaging of prostate cancer. Risk stratification of the disease is a crucial for the patients to receive most appropriate treatment, and for the clinicians to follow the patients more precisely. PSMA-PET provides non-invasive biomarkers for the risk assessment of prostate cancer, offering prediction of clinical outcomes. PROMISE criteria have been developed as comprehensive and integrated framework demonstrating association with overall survival. In this review, we aim to provide a brief update of the prognostic value of PSMA-PET for risk assessment in prostate cancer.
Related Concept Videos
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
Sensitivity, Specificity, and Predicted Value
Sensitivity is the...

